Literature DB >> 12427358

Cytokines and juvenile idiopathic arthritis.

Patricia Woo1.   

Abstract

Cytokines are a large group of polypeptides and small proteins that are effector molecules for cells involved in immune and inflammatory responses. There are agonists and antagonists that interact with each other to maintain a dynamic equilibrium, and ensure eventual recovery of any perturbation, for example, by trauma or infection, of the network toward inflammation. The imbalance between pro- and anti-inflammatory cytokines and the T helper cell subtypes is considered important in the pathogenesis of autoimmune diseases, including juvenile idiopathic arthritis. The measurement of cytokines and chemotactic cytokines in body fluids and synovial tissue has provided insight into the type of immune and inflammatory reaction and the possible presence or absence of regulation. Differences between subtypes of juvenile idiopathic arthritis have been identified with these measurements. But cytokine measurements in serum are not useful for diagnostic purposes, because of the variability during 24 hours, the collection and assay methods, as well as the ease of degradation for most cytokines. The recent interest in the genetic polymorphisms of cytokine genes and their association with juvenile idiopathic arthritis has provided association with a number of cytokine alleles. Confirmation of linkage with disease is only available for tumor necrosis factor and interleukin-6 at present. These genetic variants may be the basis of genetic susceptibility to the persistent imbalance in the inflammatory and immune networks, and determine the phenotype and severity of disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427358     DOI: 10.1007/s11926-002-0050-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  49 in total

1.  Chemokine receptor CCR4 on CD4+ T cells in juvenile rheumatoid arthritis synovial fluid defines a subset of cells with increased IL-4:IFN-gamma mRNA ratios.

Authors:  S D Thompson; L K Luyrink; T B Graham; M Tsoras; M Ryan; M H Passo; D N Glass
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

2.  Circulating levels of soluble E-selectin, P-selectin and intercellular adhesion molecule-1 in patients with juvenile idiopathic arthritis.

Authors:  F De Benedetti; M Vivarelli; P Pignatti; M Oliveri; M Massa; A Pistorio; A Martini
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

3.  Haplotype associated with low interleukin-10 production in patients with severe asthma.

Authors:  S Lim; E Crawley; P Woo; P J Barnes
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

4.  The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men.

Authors:  S E Humphries; L A Luong; M S Ogg; E Hawe; G J Miller
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

5.  Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.

Authors:  E Crawley; R Kay; J Sillibourne; P Patel; I Hutchinson; P Woo
Journal:  Arthritis Rheum       Date:  1999-06

6.  Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis.

Authors:  L R Wedderburn; N Robinson; A Patel; H Varsani; P Woo
Journal:  Arthritis Rheum       Date:  2000-04

7.  Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist.

Authors:  L C Miller; S Isa; E Vannier; K Georgilis; A C Steere; C A Dinarello
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

9.  A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis.

Authors:  R Keul; P C Heinrich; G Müller-newen; K Muller; P Woo
Journal:  Cytokine       Date:  1998-09       Impact factor: 3.861

10.  Elevated soluble CD8 antigen and soluble interleukin-2 receptors in the sera of patients with juvenile rheumatoid arthritis.

Authors:  R N Lipnick; P P Sfikakis; G L Klipple; G C Tsokos
Journal:  Clin Immunol Immunopathol       Date:  1993-07
View more
  9 in total

1.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

Review 2.  Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Takako Miyamae; Tomoyuki Imagawa; Shigeki Katakura; Rumiko Kurosawa; Masaaki Mori
Journal:  Clin Rev Allergy Immunol       Date:  2005-06       Impact factor: 8.667

3.  Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis.

Authors:  L Breda; D Di Marzio; C Giannini; S Gaspari; M Nozzi; A Scarinci; F Chiarelli; A Mohn
Journal:  Clin Res Cardiol       Date:  2012-08-11       Impact factor: 5.460

4.  Tuberculin skin test and ELISPOT/T. SPOT.TB in children and adolescents with juvenile idiopathic arthritis.

Authors:  Flavio Sztajnbok; Neio L F Boechat; Samantha B Ribeiro; Sheila K F Oliveira; Denise C N Sztajnbok; Clemax C Sant'Anna
Journal:  Pediatr Rheumatol Online J       Date:  2014-05-22       Impact factor: 3.054

5.  The profile of polyunsaturated fatty acids in juvenile idiopathic arthritis and association with disease activity.

Authors:  Daiva Gorczyca; Jacek Postępski; Aleksandra Czajkowska; Mariola Paściak; Anna Prescha; Edyta Olesińska; Anna Gruenpeter; Iwona Lachór-Motyka; Bogumiła Szponar
Journal:  Clin Rheumatol       Date:  2017-02-28       Impact factor: 2.980

6.  Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission.

Authors:  Inmaculada Concepción Aranda-Valera; Iván Arias de la Rosa; Rosa Roldán-Molina; María Del Carmen Ábalos-Aguilera; Carmen Torres-Granados; Alejandra Patiño-Trives; María Luque-Tevar; Alejandro Ibáñez-Costa; Rocío Guzmán-Ruiz; María Del Mar Malagón; Alejandro Escudero-Contreras; Chary López-Pedrera; Eduardo Collantes-Estévez; Nuria Barbarroja
Journal:  Pediatr Rheumatol Online J       Date:  2020-07-14       Impact factor: 3.054

7.  T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis.

Authors:  Ian D Ferguson; Patricia Griffin; Joshua J Michel; Hiroshi Yano; Sarah L Gaffen; Robert G Mueller; Jeffrey A Dvergsten; Jon D Piganelli; Margalit E Rosenkranz; Daniel A Kietz; Abbe N Vallejo
Journal:  Front Immunol       Date:  2018-08-06       Impact factor: 7.561

8.  Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication.

Authors:  Boris Hügle; Manuela Krumrey-Langkammerer; Johannes-Peter Haas
Journal:  Pediatr Rheumatol Online J       Date:  2021-11-29       Impact factor: 3.054

9.  Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular point. Part I: histological effects.

Authors:  Kasper D Kristensen; Peter Stoustrup; Annelise Küseler; Thomas K Pedersen; Jens R Nyengaard; Ellen Hauge; Troels Herlin
Journal:  Pediatr Rheumatol Online J       Date:  2009-02-06       Impact factor: 3.054

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.